'Vascular event' diaporamas de présentation

My Head is Better but How About My Heart Health?

384 views • 38 slides

Baseline characteristics of HPS participants by prior diabetes

Baseline characteristics of HPS participants by prior diabetes. HPS: Baseline lipids (mmol/L) and apolipoproteins (g/L) by prior diabetes. HPS: Baseline lipids (mg/dL) and apolipoproteins (g/L) by prior diabetes. HPS: FACTORIAL TREATMENT COMPARISONS.

370 views • 25 slides

Baseline characteristics of HPS participants by prior diabetes

Baseline characteristics of HPS participants by prior diabetes. HPS: Baseline lipids (mmol/L) and apolipoproteins (g/L) by prior diabetes. HPS: Baseline lipids (mg/dL) and apolipoproteins (g/L) by prior diabetes. HPS: FACTORIAL TREATMENT COMPARISONS.

331 views • 25 slides

Baseline characteristics of HPS participants by prior diabetes

Baseline characteristics of HPS participants by prior diabetes. HPS: Baseline lipids (mmol/L) and apolipoproteins (g/L) by prior diabetes. HPS: Baseline lipids (mg/dL) and apolipoproteins (g/L) by prior diabetes. HPS: FACTORIAL TREATMENT COMPARISONS.

253 views • 25 slides

Economic evaluation of MRC/BHF Heart Protection Study

Economic evaluation of MRC/BHF Heart Protection Study. Heart Protection Study Collaborative Group University of Oxford UK. HPS: Eligibility criteria. Increased risk of CHD death due to prior disease: Myocardial infarction or other CHD; Occlusive disease of non-coronary arteries; or

553 views • 23 slides

Economic evaluation of MRC/BHF Heart Protection Study

Economic evaluation of MRC/BHF Heart Protection Study. Heart Protection Study Collaborative Group University of Oxford UK. HPS: Eligibility criteria. Increased risk of CHD death due to prior disease: Myocardial infarction or other CHD; Occlusive disease of non-coronary arteries; or

331 views • 23 slides

Economic evaluation of MRC/BHF Heart Protection Study

Economic evaluation of MRC/BHF Heart Protection Study. Heart Protection Study Collaborative Group University of Oxford UK. HPS: Eligibility criteria. Increased risk of CHD death due to prior disease: Myocardial infarction or other CHD; Occlusive disease of non-coronary arteries; or

232 views • 23 slides

Stroke Prevention in Atrial Fibrillation An Expert Commentary With Freek W.A. Verheugt, MD, FACC, FESC A Clinical Conte

Stroke Prevention in Atrial Fibrillation An Expert Commentary With Freek W.A. Verheugt, MD, FACC, FESC A Clinical Context Report. Jointly Sponsored by: and. Stroke Prevention in Atrial Fibrillation Expert Commentary. Stroke Prevention in Atrial Fibrillation Expert Commentary.

351 views • 22 slides

Turlure P et al. Proc ASH 2011;Abstract 280.

Complete Hematological Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon a -2a (peg-IFN a -2a) Therapy in Polycythemia Vera (PV): Long Term Results of a Phase 2 Trial. Turlure P et al. Proc ASH 2011;Abstract 280. Background.

154 views • 8 slides